- Home
- ACRS vs ISRL Comparison
ACRS vs ISRL Comparison
Compare ACRS & ISRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- ISRL
- Stock Information
- Founded
- ACRS 2012
- ISRL 2021
- Country
- ACRS United States
- ISRL United States
- Employees
- ACRS N/A
- ISRL N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- ISRL Blank Checks
- Sector
- ACRS Health Care
- ISRL Finance
- Exchange
- ACRS Nasdaq
- ISRL Nasdaq
- Market Cap
- ACRS 132.0M
- ISRL 144.2M
- IPO Year
- ACRS 2015
- ISRL 2023
- Fundamental
- Price
- ACRS $4.32
- ISRL $11.28
- Analyst Decision
- ACRS Buy
- ISRL
- Analyst Count
- ACRS 6
- ISRL 0
- Target Price
- ACRS $7.20
- ISRL N/A
- AVG Volume (30 Days)
- ACRS 6.0M
- ISRL 15.1K
- Earning Date
- ACRS 11-06-2024
- ISRL 01-01-0001
- Dividend Yield
- ACRS N/A
- ISRL N/A
- EPS Growth
- ACRS N/A
- ISRL N/A
- EPS
- ACRS N/A
- ISRL N/A
- Revenue
- ACRS $27,079,000.00
- ISRL N/A
- Revenue This Year
- ACRS N/A
- ISRL N/A
- Revenue Next Year
- ACRS N/A
- ISRL N/A
- P/E Ratio
- ACRS N/A
- ISRL $37.46
- Revenue Growth
- ACRS 26.35
- ISRL N/A
- 52 Week Low
- ACRS $0.77
- ISRL $10.62
- 52 Week High
- ACRS $5.17
- ISRL $11.28
- Technical
- Relative Strength Index (RSI)
- ACRS 74.71
- ISRL 65.07
- Support Level
- ACRS $3.67
- ISRL $11.26
- Resistance Level
- ACRS $5.17
- ISRL $11.26
- Average True Range (ATR)
- ACRS 0.47
- ISRL 0.01
- MACD
- ACRS 0.20
- ISRL -0.00
- Stochastic Oscillator
- ACRS 72.93
- ISRL 100.00
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About ISRL Israel Acquisitions Corp
Israel Acquisitions Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.